Present results and future perspectives in optimizing CML therapy

Angelo M. Carella, Giuseppe Saglio, Xavier F. Mahon, and Michael J. Mauro

Disclosures: AMC: Conflict of interest: None XFM: Consulting or Advisory Role: Novartis, Bristol-Myers Squibb Research Funding: Novartis BS: Consulting and advisory role for Novartis, BMS, Ariad, Incyte and Pfizer. MJM: Novartis, Bristol Myers Squibb, Pfizer, Ariad, Takeda: Advisory Novartis, Takeda: Research Funding (to the institution, MSKCC, not to me individually)

Contributions: AMC: was responsible for the project and organization of the Editorial; FXM performed the Cessation therapy Section; GS discussed the first-line therapy and MJM gave some new ideas for the future and revised the English text.